This particular study is unique because it specifically examined patients taking GLP-1s who are at high risk of suicidality a population that previous research on GLP-1s has largely excluded. In a related editorial, Peter Ueda, MD, PhD, an assistant professor at Karolinska Institutet in Sweden, and Bjrn Pasternak, MD, PhD, an associate professor and principal researcher at the same institution, applauded the carefully conducted study but also noted some limitations, including that less than 10% of the patients in the study used semaglutide, the most popular GLP-1 receptor agonist
Imaging 47 , 20102015 (2020)
Li YF, Gauderman WJ, Conti DV, Lin PC, Avol E, Gilliland FD
Who is a good candidate for Medically Guided Weight Loss
Step 2: Personalized Plan If lipotropic injections are right for you, well create a weight loss plan that may include nutritional guidance, exercise recommendations, and other supportive therapies